Navigation Links
One-Third of Patients Discontinue Common Breast Cancer Therapy

PRINCETON, N.J.--(BUSINESS WIRE)--Mar 15, 2007 - An alarming study that appeared in the March 1, 2007 issue of CANCER (a peer-reviewed journal of the American Cancer Society), reports that one-third of women taking the standard five-year regimen of the hormonal breast cancer treatment tamoxifen citrate, discontinue therapy early.(1)

According to the authors, non-compliance with tamoxifen tablets is a major issue that may negatively affect treatment efficacy. While tamoxifen tablets remain a standard of care, according to these data, they are associated with compliance and persistency issues. Oncologists need to identify those at risk of non-persistence and develop strategies to combat this barrier to treatment success.

Patients at risk of non-persistence include those who prefer alternative delivery formats to traditional pills/tablets, such as liquid formulations. SOLTAMOX, the only liquid form of tamoxifen citrate, is an alternative for women who require tamoxifen therapy. SOLTAMOX may be an attractive option for women who do not like pills or cannot swallow pills. SOLTAMOX is approved by the FDA and is available in the U.S. through Cytogen Corporation. For more information about SOLTAMOX, please visit www.soltamoxus.com. -0-

WHO:   Linda Vahdat, MD, Weill Cornell Medical Center. Dr. Vahdat is a

        leading breast cancer expert and a participant in the

        Compliance Strategic Initiative -- a program designed to

        increase awareness compliance and to raise awareness

        importance of hormonal therapy in breast cancer.


WHAT:  Dr. Vahdat is available to speak with media regarding the

        importance of tamoxifen compliance and the need to offer

        patients more options.


WHEN:  March 2007


WHERE: Please contact Eliza Schleifstein (973) 387-0342 to set up a

        convenient time to interview Dr. Vahdat.

About SOLTAMOX

SOLTAMOX (tamoxifen c
'"/>




Page: 1 2 3

Related medicine technology :

1. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
2. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
3. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
4. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
5. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
6. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
7. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
8. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
9. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
10. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
11. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: One Third Patients Discontinue Common Breast Cancer Therapy
(Date:9/2/2015)... Sept. 2, 2015 Advanced Wound Dressings ... Advanced dressings have steadily replaced traditional bandages ... variety of wound indications, such as trauma wounds, ... control, and physical protection become increasingly critical in ... in standard therapy. This report focuses on ...
(Date:9/2/2015)... 2, 2015 STAAR Surgical Company (NASDAQ: STAA ... and delivery systems for the eye, today announced that its ... to the Company,s Board. Mr. Wall was ... Boston -based investment firm, for more than nine years. ... Directors, and chair of the Corporate Governance Committee and member ...
(Date:9/2/2015)... , Sep. 02, 2015 Research and ... Regulatory Affairs in Latin America (London, UK - November 16-18, 2015)" ... across Latin America including Columbia, Peru ... Argentina , Uruguay , ... , Central America , Chile ...
Breaking Medicine Technology:Advanced Wound Dressings - 5EU Analysis and Market Forecasts 2William P. Wall Appointed to STAAR Surgical Board of Directors 2Pharmaceutical Regulatory Affairs in Latin America Seminar - London, UK - November 16-18, 2015 2
... Fla. and NEW YORK, Sept. 28 ... development company, announced today that it has completed ... Stock resulting in gross proceeds of approximately $6.5 ... Neil Flanzraich, also included current investors Wexford Spectrum ...
... (NYSE: BSX ) today welcomed the publication ... II clinical trial in the current issue of ... of implantable cardioverter defibrillator (ICD) therapy are sustained at ... data regarding the benefits of ICDs in a primary ...
Cached Medicine Technology:Tigris Pharmaceuticals, Inc. Completes $6.5 Million Private Placement 2Tigris Pharmaceuticals, Inc. Completes $6.5 Million Private Placement 3Boston Scientific Welcomes Publication of Analysis Demonstrating Long-Term Survival Benefit for ICD Therapy 2Boston Scientific Welcomes Publication of Analysis Demonstrating Long-Term Survival Benefit for ICD Therapy 3
(Date:9/2/2015)... ... September 02, 2015 , ... Based in Beverly Hills, Luxury Line Auto ... luxury vehicles based on which of the latest and greatest vehicles their customers want ... in pursuit of this goal: a 2015 Rolls Royce Wraith rental in Los ...
(Date:9/2/2015)... ... September 02, 2015 , ... In “Failure Lab: Weight Loss Surgery ... on August 25th, writer Akela Stanfield detailed her lifelong struggle with obesity that eventually ... she had always seen herself as someone who would lose weight through sheer self-control, ...
(Date:9/2/2015)... ... 2015 , ... Care Providers and their medical billing service ... EOBs, payments, and payment related documents. AD-EOB A/R helps them sort, index and ... with one efficient process and interface,“ stated Rich Caproni, AliusDoc’s Director of Business ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... academic partnership has earned international recognition as a premier center for treatment of ... cause sudden, catastrophic internal bleeding and stroke. , Cure HHT, previously known ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... companies, has completed a recapitalization with new investment partners Beecken Petty O’Keefe ... Group each offer extensive expertise and connections within the healthcare industry, which ...
Breaking Medicine News(10 mins):Health News:Luxury Line Auto Rental Announces Addition of the Rolls Royce Wraith to their Luxury Fleet 2Health News:Recent Editorial on Bariatric Surgery Acceptance Illuminates a Typical Journey Towards Weight Loss Surgery, Notes Dr. Michael Feiz 2Health News:AliusDoc Launches Enhanced AD-EOB A/R Data Capture Solution to Streamline Processing of Payment-Related Documents Together with EOBs 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 3Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 4
... Response Essentially Met but Donations Still Needed to Prepare,for ... WASHINGTON, May 5 The American Red Cross,today ... the Southeastern,Virginia tornadoes but donations to its Disaster Relief ... the next disaster, particularly with the,beginning of hurricane season ...
... Integrated Approach, WASHINGTON, May 5 ... Kenya, and Tanzania -- face the interconnected,challenges ... environmental,degradation. But some innovative development programs are ... linked problems., On May 8th, three ...
... SYDNEY, Australia, May 5 ,HeartWare Limited (ASX: HTW) ... the United States Food and Drug Administration,(FDA) of ... product,the HeartWare(R) Left Ventricular Assist System (LVAS)., ... FDA enables the Company,to immediately commence its U.S. ...
... growth factor receptor found abundantly on the surface of ... also protects tumor cells from starvation by a newly ... D. Anderson Cancer Center report in the May 5 ... receptor (EGFR) stabilizes another cell membrane protein that channels ...
... cancerous, study shows , , MONDAY, May 5 (HealthDay News) ... starts harmless colon polyps on their journey to becoming ... Helsinki research, published online in Cancer Cell , ... of normal organs in embryos, is produced in excess ...
... 4, 2008 MedImmune today announced that researchers ... 3 study involving motavizumab, an investigational monoclonal antibody ... to prevent serious disease caused by respiratory syncytial ... OBrien, M.D., M.P.H., associate professor at the Center ...
Cached Medicine News:Health News:Generous Donors Allow Red Cross to Respond Swiftly and Effectively to Southeastern Virginia Tornadoes 2Health News:Generous Donors Allow Red Cross to Respond Swiftly and Effectively to Southeastern Virginia Tornadoes 3Health News:East African Experts Discuss Population, Health, Environment at Wilson Center 2Health News:HeartWare Receives Conditional Approval of IDE 2Health News:HeartWare Receives Conditional Approval of IDE 3Health News:Unexpected role: EGFR protects cancer cells from starving 2Health News:Unexpected role: EGFR protects cancer cells from starving 3Health News:Phase 3 data Re: Anti-RSV antibody to be presented at Pediatric Academic Societies Annual Meeting 2
... a leading provider of immunofluorescence assays, with ... that includes kits for autoimmune diseases, infectious ... conjugates and components. Our Impact IFA Test ... substrates and kit sizes to choose from. ...
... Inverness Medical Professional Diagnostics is a leading ... IFA and DFA test menu that includes ... STDs as well as miscellaneous conjugates and ... you a wide assortment of substrates and ...
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
Medicine Products: